Cyclosporin Compositions
Disclosed herein are therapeutic methods, compositions, and medicaments related to cyclosporine.
1 . A method of treating loss of corneal sensitivity comprising administering a composition comprising cyclosporin A at a concentration of from about 0.0001% (w/v) to less than about 0.05% (w/v) to a person in need thereof.
2 . The method of claim 1 wherein the composition comprises cyclosporin A at a concentration of from 0.01% (w/v) to 0.02% (w/v) and a preservative.
3 . The method of claim 2 wherein the concentration of cyclosporin A in the composition is about 0.015% (w/v).
4 . The method of claim 1 wherein the concentration of cyclosporin A in the composition about 0.04% (w/v).
5 . The method of claim 1 wherein the concentration of cyclosporin A in the composition is about 0.005% (w/v).
6 . The method of claim 1 wherein the loss of corneal sensitivity is related to surgery affecting the cornea or viral infection.
7 . The method of claim 6 wherein the loss of corneal sensitivity is associated with keratorefractive surgery or penetrating keratoplasty.
8 . The method of claim 7 wherein the loss of corneal sensitivity is caused by the person having radial keratotomy.
9 . The method of claim 7 wherein the loss of corneal sensitivity is caused by photorefractive keratotomy.
10 . The method of claim 7 wherein the loss of corneal sensitivity is caused by laser-assisted in situ keratomileusis.
11 . The method of claim 7 wherein the loss of corneal sensitivity is caused by laser assisted sub-epithelial keratomileusis.
12 . The method of claim 7 wherein the loss of corneal sensitivity is caused by SB-LASIK.
13 . The method of claim 7 wherein the loss of corneal sensitivity is caused by EPI-LASIK.
14 . The method of claim 6 wherein the loss of corneal sensitivity is caused by viral infection.
15 . The method of claim 14 wherein the viral infection is HSV-1.
16 . The method of claim 14 wherein the viral infection is HSV-2.
17 . The method of claim 14 wherein the viral infection is VZV.
18 . The method of claim 2 wherein the concentration of cyclosporin A in the composition is about 0.0015% (w/v).
19 . A liquid composition comprising cyclosporin A at a concentration of about 0.0015% (w/v).